Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padrón LJ, Sharma P

Open source

DOI: 10.1084/jem.20240152
Published: 2024 Oct 7
Container: The Journal of experimental medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1084/jem.20240152,
  title = {Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.},
  author = {Tsimberidou AM and Alayli FA and Okrah K and Drakaki A and Khalil DN and Kummar S and Khan SA and Hodi FS and Oh DY and Cabanski CR and Gautam S and Meier SL and Amouzgar M and Pfeiffer SM and Kageyama R and Yang E and Spasic M and Tetzlaff MT and Foo WC and Hollmann TJ and Li Y and Adamow M and Wong P and Moore JS and Velichko S and Chen RO and Kumar D and Bucktrout S and Ibrahim R and Dugan U and Salvador L and Hubbard-Lucey VM and O'Donnell-Tormey J and Santulli-Marotto S and Butterfield LH and Da Silva DM and Fairchild J and LaVallee TM and Padrón LJ and Sharma P},
  year = {2024},
  journal = {The Journal of experimental medicine},
  doi = {10.1084/jem.20240152},
  url = {https://doi.org/10.1084/jem.20240152}
}

RIS

TY  - JOUR
TI  - Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
AU  - Tsimberidou AM
AU  - Alayli FA
AU  - Okrah K
AU  - Drakaki A
AU  - Khalil DN
AU  - Kummar S
AU  - Khan SA
AU  - Hodi FS
AU  - Oh DY
AU  - Cabanski CR
AU  - Gautam S
AU  - Meier SL
AU  - Amouzgar M
AU  - Pfeiffer SM
AU  - Kageyama R
AU  - Yang E
AU  - Spasic M
AU  - Tetzlaff MT
AU  - Foo WC
AU  - Hollmann TJ
AU  - Li Y
AU  - Adamow M
AU  - Wong P
AU  - Moore JS
AU  - Velichko S
AU  - Chen RO
AU  - Kumar D
AU  - Bucktrout S
AU  - Ibrahim R
AU  - Dugan U
AU  - Salvador L
AU  - Hubbard-Lucey VM
AU  - O'Donnell-Tormey J
AU  - Santulli-Marotto S
AU  - Butterfield LH
AU  - Da Silva DM
AU  - Fairchild J
AU  - LaVallee TM
AU  - Padrón LJ
AU  - Sharma P
PY  - 2024
JO  - The Journal of experimental medicine
DO  - 10.1084/jem.20240152
UR  - https://doi.org/10.1084/jem.20240152
ER  -

APA

AM, T., FA, A., K, O., A, D., DN, K., S, K., SA, K., FS, H., DY, O., CR, C., S, G., SL, M., M, A., SM, P., R, K., E, Y., M, S., MT, T., WC, F., TJ, H., Y, L., M, A., P, W., JS, M., S, V., RO, C., D, K., S, B., R, I., U, D., L, S., VM, H., J, O., S, S., LH, B., DM, D. S., J, F., TM, L., LJ, P., & P, S. (2024). Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.. The Journal of experimental medicine. https://doi.org/10.1084/jem.20240152

Source records

pubmed · retrieved 2026-09-27T09:49:47.958Z